Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Shock, inflammation and PARP.

Salvatore Cuzzocrea1

  • 1Institute of Pharmacology, University of Messina, Torre Biologica, Policlinico Universitario Via C. Valeria, Gazzi, 98100 Messina, Italy. salvator@unime.it

Pharmacological Research
|May 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma.

Journal of neurotrauma·2018
Same author

Anti-inflammatory effect of ATB-352, a H2S -releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats.

Pharmacological research·2017
Same author

An In Vivo Compression Model of Spinal Cord Injury.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

A Controlled Cortical Impact Preclinical Model of Traumatic Brain Injury.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

Middle Cerebral Artery Occlusion by an Intraluminal Suture Method.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial.

International immunopharmacology·2017
Same journal

Ketohexokinase: A central mediator of fructose-associated pathogenesis and promising therapeutic target.

Pharmacological research·2026
Same journal

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.

Pharmacological research·2026
Same journal

Cajaninstilbene acid in macrophage immunometabolism and angiogenesis: Mechanisms and therapeutic potential.

Pharmacological research·2026
Same journal

From Mechanisms to Therapy: Targeting the Gut-Brain Axis in Chronic Gastrointestinal Pain.

Pharmacological research·2026
Same journal

Natural product emodin-based nanodrug delivery systems: Advancements and applications.

Pharmacological research·2026
Same journal

Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma.

Pharmacological research·2026
See all related articles

Poly(ADP-ribose) polymerase (PARP) activation contributes to inflammation and shock by causing cell damage. Inhibiting PARP shows beneficial effects in various models of acute and chronic inflammation.

Area of Science:

  • Biochemistry
  • Cellular Biology
  • Pathophysiology

Background:

  • Poly(ADP-ribose) polymerase (PARP) activation is implicated in inflammation and shock.
  • Reactive oxygen species (ROS) and oxidants like peroxynitrite mediate inflammation and shock.
  • ROS can cause DNA damage, activating PARP and leading to cell energy depletion and death.

Purpose of the Study:

  • To review experimental evidence on PARP's role in acute and chronic inflammation.
  • To highlight PARP as a key pathophysiological modulator.

Main Methods:

  • Review of experimental studies on PARP inhibition.
  • Examination of cell culture, rodent, and large animal models.

Main Results:

Related Experiment Videos

  • PARP activation is linked to cell death via DNA damage and energy depletion.
  • PARP inhibition demonstrates beneficial effects in various inflammation models.
  • Evidence supports PARP's role in modulating acute and chronic inflammatory conditions.

    • Conclusions:

    • PARP plays a significant role in the pathophysiology of inflammation and shock.
    • PARP inhibition is a promising therapeutic strategy for inflammatory diseases.